Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica
|
October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]
Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Plos One
|
December 3, 2014
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals
Marta Massanella, Dan Ouchi, Silvia Marfil, et al.
The Journal of Antimicrobial Chemotherapy
|
September 2, 2017
Imbalance in mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART with obstetric complications
Mariona Guitart-Mampel, A Sandra Hernandez, Constanza Moren, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Juan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 26, 2008
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)
Angeles Jaén, Anna Esteve, Josep M Miró, et al.
Medicina Clinica
|
April 26, 2005
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]
Angeles Jaén, Jordi Casabona, Anna Esteve, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
The Journal of Antimicrobial Chemotherapy
|
February 19, 2014
Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS)
Consuelo Viladés, Xavier Escoté, Miguel López-Dupla, et al.
Current HIV Research
|
September 28, 2007
HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors
Joaquim Peraire, Oscar Miró, Maria Saumoy, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Enfermedades Infecciosas Y Microbiologia Clinica
|
October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]
Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Plos One
|
December 3, 2014
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals
Marta Massanella, Dan Ouchi, Silvia Marfil, et al.
The Journal of Antimicrobial Chemotherapy
|
September 2, 2017
Imbalance in mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART with obstetric complications
Mariona Guitart-Mampel, A Sandra Hernandez, Constanza Moren, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Juan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 26, 2008
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)
Angeles Jaén, Anna Esteve, Josep M Miró, et al.
Medicina Clinica
|
April 26, 2005
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]
Angeles Jaén, Jordi Casabona, Anna Esteve, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
The Journal of Antimicrobial Chemotherapy
|
February 19, 2014
Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS)
Consuelo Viladés, Xavier Escoté, Miguel López-Dupla, et al.
Current HIV Research
|
September 28, 2007
HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors
Joaquim Peraire, Oscar Miró, Maria Saumoy, et al.
Page
of 7